Advertisement
Advertisement
U.S. markets close in 4 hours 57 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cognetivity Neurosciences Ltd (1UB.MU)

Munich - Munich Delayed Price. Currency in EUR
0.1815-0.0070 (-3.71%)
As of 08:01AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1885
Open0.1815
Bid0.1645 x N/A
Ask0.1880 x N/A
Day's Range0.1815 - 0.1815
52 Week Range0.1375 - 0.3860
Volume2,000
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateDec 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 1UB.MU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Cognetivity Neurosciences' CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease-Modifying Therapy

      Demonstrable sensitivity and clinical usability of Cognetivity's screening and monitoring tool leaves the company well placed to support the dawning era of targeted therapies for neurodegenerative disease Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer env

    • Newsfile

      Cognetivity Neurosciences Provides Update on 2022 Corporate Achievements

      Key achievements in 2022 included continued collaboration with global pharmaceutical firms working in neurodegenerative disease, new and ongoing commercial deployments spanning three continents, and completion of a fundraising round worth CAD 4.5 million Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platfo

    • Newsfile

      Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK

      Policy paper published by UK's leading dementia research charity emphasizes importance of early detection in dementia diagnosis, citing Cognetivity's CognICA(TM) as an innovative solution for use in primary care Vancouver, British Columbia--(Newsfile Corp. - December 13, 2022) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and cons

    Advertisement
    Advertisement